Opus Genetics, Inc. (IRD)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Opus Genetics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | 4.24 | 4.25 | 4.15 | 4.20 | 17,624 |
| Nov 6, 2026 | 4.02 | 4.24 | 4.01 | 4.18 | 784,743 |
| Nov 5, 2026 | 4.26 | 4.26 | 3.79 | 4.00 | 1,473,849 |
| Nov 4, 2026 | 4.05 | 4.32 | 3.98 | 4.27 | 1,163,236 |
| Nov 3, 2026 | 3.74 | 3.99 | 3.74 | 3.93 | 1,129,727 |
| Nov 2, 2026 | 3.67 | 3.78 | 3.61 | 3.70 | 878,199 |
| Oct 30, 2026 | 3.58 | 3.69 | 3.42 | 3.67 | 1,020,250 |
| Oct 29, 2026 | 3.68 | 3.82 | 3.60 | 3.65 | 709,596 |
| Oct 28, 2026 | 3.44 | 3.69 | 3.40 | 3.68 | 1,033,421 |
| Oct 27, 2026 | 3.32 | 3.53 | 3.28 | 3.46 | 1,304,158 |
| Oct 26, 2026 | 3.49 | 3.50 | 3.23 | 3.32 | 1,520,405 |
| Oct 23, 2026 | 3.79 | 3.83 | 3.44 | 3.47 | 1,118,007 |
| Oct 22, 2026 | 4.04 | 4.10 | 3.80 | 3.82 | 894,737 |
| Oct 21, 2026 | 4.03 | 4.21 | 4.00 | 4.12 | 1,355,926 |
| Oct 20, 2026 | 3.82 | 4.14 | 3.78 | 4.01 | 1,461,228 |
| Oct 19, 2026 | 3.87 | 3.94 | 3.69 | 3.82 | 1,527,759 |
| Oct 16, 2026 | 4.12 | 4.13 | 3.75 | 3.84 | 2,531,554 |
| Oct 15, 2026 | 4.15 | 4.28 | 3.98 | 4.05 | 2,952,928 |
| Oct 14, 2026 | 4.39 | 4.39 | 4.08 | 4.10 | 1,199,926 |
| Oct 13, 2026 | 4.76 | 4.77 | 4.23 | 4.24 | 1,294,117 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Magrath George | Chief Executive Officer | Sale | 28.3K | $110.2K | Nov 3, 2026 |
 YERXA BENJAMIN R | President | Sale | 25.5K | $90.1K | Oct 23, 2026 |
 SCHACHLE JOSEPH K | Chief Operating Officer | Sale | 4.8K | $17.0K | Oct 23, 2026 |
| YERXA BENJAMIN R | President | Sale | 7.7K | $27.2K | Oct 23, 2026 |
 Gagnon Robert E. | Chief Financial Officer | Sale | 14.0K | $49.6K | Oct 23, 2026 |
| Magrath George | Chief Executive Officer | Sale | 9.6K | $34.4K | Oct 23, 2026 |
Insiders
- Magrath GeorgeChief Executive Officer
- YERXA BENJAMIN RPresident
- SCHACHLE JOSEPH KChief Operating Officer
- Gagnon Robert E.Chief Financial Officer
- Foundation Fighting Blindness Retinal Degeneration FundDirector
- Gallagher CamDirector
- Jayagopal AshwathChief Scientific & Dev. Ofc.
- Zaremba Rabourn AmyHead of Fin. Quality Assurance
- Ainsworth SeanDirector
- Bennett JeanDirector
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology.
The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders.
Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
based on 83.20M shares outstanding
US30d Avg
1.29M
60d Avg
1.74M
90d Avg
2.54M